Identify microRNAs in Cachexia in Pancreatic Carcinoma

NCT ID: NCT05275075

Last Updated: 2026-01-08

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-12-07
• Study Completion Date: 2029-05-01

Brief Summary

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Detailed Description

This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients.

Conditions

Resectable Pancreatic Adenocarcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Pancreatic Cancer Cohort

All eligible adenocarcinoma pancreatic cancer patients with operable cancer.

Pancreatic cancer microRNA and messenger RNA expression.

Intervention Type: OTHER

Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.

Interventions

Pancreatic cancer microRNA and messenger RNA expression.

Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Male or female patient, who is ≥ 18 years old at the time of informed consent.

2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.

3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.

4. Ability to provide written informed consent and HIPAA authorization.

Exclusion Criteria

1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.

2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Oklahoma

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ajay Jain, MD

Role: PRINCIPAL_INVESTIGATOR

University of Oklahoma Stephenson Cancer Center

Locations

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Lead Nurse

Role: CONTACT

scc-iit-office@ouhsc.edu

405.271.8777

Facility Contacts

Ajay Jain, MD

Role: primary

Ajay-Jain@ouhsc.edu

Other Identifiers

OU-SCC-MIRPANCA

Identifier Type: -

Identifier Source: org_study_id